Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

PubWeight™: 4.49‹?› | Rank: Top 1%

🔗 View Article (PMID 22920930)

Published in N Engl J Med on August 25, 2012

Authors

Matthew T Roe1, Paul W Armstrong, Keith A A Fox, Harvey D White, Dorairaj Prabhakaran, Shaun G Goodman, Jan H Cornel, Deepak L Bhatt, Peter Clemmensen, Felipe Martinez, Diego Ardissino, Jose C Nicolau, William E Boden, Paul A Gurbel, Witold Ruzyllo, Anthony J Dalby, Darren K McGuire, Jose L Leiva-Pons, Alexander Parkhomenko, Shmuel Gottlieb, Gracita O Topacio, Christian Hamm, Gregory Pavlides, Assen R Goudev, Ali Oto, Chuen-Den Tseng, Bela Merkely, Vladimir Gasparovic, Ramon Corbalan, Mircea Cinteză, R Craig McLendon, Kenneth J Winters, Eileen B Brown, Yuliya Lokhnygina, Philip E Aylward, Kurt Huber, Judith S Hochman, E Magnus Ohman, TRILOGY ACS Investigators

Author Affiliations

1: Duke Clinical Research Institute and Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA. matthew.roe@duke.edu

Associated clinical trials:

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects (TRILOGY ACS) | NCT00699998

Articles citing this

Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (2013) 3.43

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J (2014) 1.51

Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome. Heart (2014) 1.48

Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J (2015) 1.38

Recent advances in antithrombotic therapy after acute coronary syndrome. CMAJ (2013) 1.23

New antiplatelet agents for cardiovascular disease. CMAJ (2013) 1.09

Prasugrel versus clopidogrel for acute coronary syndromes. N Engl J Med (2013) 1.08

The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors. Dtsch Arztebl Int (2013) 1.07

Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2014) 1.05

Importance of frailty in patients with cardiovascular disease. Eur Heart J (2014) 0.96

Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J (2013) 0.96

Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets (2013) 0.91

State of the art in platelet function testing. Transfus Med Hemother (2013) 0.90

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes. Diabetes Care (2013) 0.89

Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J Am Heart Assoc (2014) 0.86

Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart (2014) 0.83

Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. World J Crit Care Med (2015) 0.82

Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol (2015) 0.82

A new paradigm shift in antithrombotic therapy. Front Pharmacol (2013) 0.81

Doubly blind: a systematic review of gender in randomised controlled trials. Glob Health Action (2016) 0.80

P2Y12-ADP receptor antagonists: Days of future and past. World J Cardiol (2016) 0.80

P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use. Ther Adv Chronic Dis (2015) 0.80

P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon? Cardiol Res Pract (2013) 0.79

The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysis. Biomed Res Int (2014) 0.78

Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. J Am Heart Assoc (2015) 0.78

Prasugrel versus clopidogrel for acute coronary syndromes. N Engl J Med (2013) 0.78

Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease. Ther Clin Risk Manag (2014) 0.77

Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. Eur J Clin Pharmacol (2014) 0.77

High-maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. PLoS One (2013) 0.77

Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease: a meta-analysis. Heart Vessels (2014) 0.77

Case scenario: a patient on dual antiplatelet therapy with an intracranial hemorrhage after percutaneous coronary intervention. Anesthesiology (2014) 0.76

Novel antiplatelet agent use for acute coronary syndrome in the emergency department: a review. Cardiol Res Pract (2013) 0.76

Significance of antiplatelet therapy in emergency myocardial infarction treatment. Postepy Kardiol Interwencyjnej (2014) 0.76

State of the art: Oral antiplatelet therapy. JRSM Cardiovasc Dis (2016) 0.75

Acute coronary syndromes in 2016: Assessing strategies to improve patient management. Nat Rev Cardiol (2017) 0.75

Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. BMC Surg (2015) 0.75

Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Heart Assoc (2016) 0.75

Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. Nat Rev Cardiol (2016) 0.75

Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients. Ther Clin Risk Manag (2015) 0.75

Oral antiplatelet therapy in acute coronary syndromes: recent developments. Cardiol Ther (2013) 0.75

Optimal oral antithrombotic regimes for patients with acute coronary syndrome: a network meta-analysis. PLoS One (2014) 0.75

Type 2 Diabetes and ADP Receptor Blocker Therapy. J Diabetes Res (2015) 0.75

Bleeding events and maintenance dose of prasugrel: BLESS pilot study. Open Heart (2016) 0.75

Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes. Am J Ther (2015) 0.75

TRIOLOGY ACS: No benefit/No harm. Glob Cardiol Sci Pract (2013) 0.75

Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. Med Sci Monit (2015) 0.75

Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications. Korean J Anesthesiol (2017) 0.75

Recent advances in treatment of acute coronary syndromes. F1000Prime Rep (2013) 0.75

Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. Eur Heart J (2015) 0.75

Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice. Vasc Health Risk Manag (2014) 0.75

Switching between thienopyridines in patients with acute myocardial infarction and quality of care. Open Heart (2016) 0.75

Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. J Am Heart Assoc (2016) 0.75

Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. Int J Cardiol (2017) 0.75

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar. Drug Des Devel Ther (2015) 0.75

Lower loading dose of prasugrel compared with conventional loading doses of clopidogrel and prasugrel in korean patients undergoing elective coronary angiography: a randomized controlled study evaluating pharmacodynamic efficacy. Korean Circ J (2014) 0.75

Systematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome. Open Heart (2016) 0.75

European society of cardiology congress 2012. P T (2012) 0.75

Comparison of prasugrel and clopidogrel in the setting of ACS without revascularization. Nat Rev Cardiol (2012) 0.75

Dual antiplatelet therapy and newer agents: More efficacy but lets keep the brain safe!! Indian Heart J (2015) 0.75

Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial. Trials (2015) 0.75

Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study. Yonsei Med J (2017) 0.75

To Pretreat or Not to Pretreat (With Oral P2Y12 Antagonists)? That is the Question. J Am Heart Assoc (2017) 0.75

Substitutes of Prescription Medicines - A Review of Concerns Relevant to Doctors and Patients. J Clin Diagn Res (2017) 0.75

Management of elderly patients with a non-ST-segment-elevation acute coronary syndrome. Neth Heart J (2017) 0.75

Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. J Am Heart Assoc (2017) 0.75

The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease. Cardiovasc Drugs Ther (2017) 0.75

Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. Drug Saf (2017) 0.75

Articles by these authors

Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18

Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 16.52

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J (2012) 16.00

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90

Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med (2012) 13.59

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25

Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J (2011) 13.10

Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke (2007) 12.77

Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10

Universal definition of myocardial infarction. Circulation (2007) 11.69

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34

Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med (2004) 11.09

Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med (2014) 10.66

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2012) 10.38

Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med (2011) 10.29

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol (2007) 10.19

Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J (2014) 9.73

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13

Universal definition of myocardial infarction. Eur Heart J (2007) 9.04

Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93

Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85

Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74

Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69

Universal definition of myocardial infarction. J Am Coll Cardiol (2007) 8.68

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

Third universal definition of myocardial infarction. Circulation (2012) 8.47

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2008) 8.20

Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med (2010) 8.17

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 7.99

Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94

Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation (2004) 7.72

Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70

Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55

2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54

A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32

Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30

Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med (2003) 7.25

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94

Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86

Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84

Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80

Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation (2007) 6.78

Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med (2011) 6.65

2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2009) 6.61

Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51